

<b>Reference:</b>	FOI.20078.26
<b>Subject:</b>	Injectable weight loss medication
<b>Date of Request:</b>	1 April 2026

**Requested:**

Under the Freedom of Information Act 2000, I would like to request the following information regarding the use of injectable pharmacological treatments for overweight and obesity (e.g. GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists).

For the period from 1 September 2024 to 1 April 2026:

1. Are injectable pharmacological treatments for overweight and obesity currently being initiated for patients as part of routine services commissioned or delivered by your organisation?
  - a. If so, please identify which medication(s) are currently used as first-line injectable pharmacological therapy for overweight and obesity within commissioned services.
2. What are the eligibility criteria for patients to access injectable pharmacological treatments for overweight and obesity within your organisation?  
Where these criteria are already published online, please provide the relevant link and confirm whether the published criteria are currently being applied in practice.
3. Please confirm whether the model of care through which these treatments are (or will be) delivered:
  - Directly from general practice
  - Primary care-led weight management service (e.g. GP or pharmacist-led weight management service, community weight management hub, etc.)
  - Tier 3 specialist weight management services
  - Other (please specify).
4. Please confirm whether the relevant pathway within your organisation is currently:
  - operational and accepting referrals
  - operational but limited (e.g. pilot sites)
  - approved but not yet implemented
  - currently under development.
5. Please provide copies of any key or current clinical pathways, service specifications, prescribing guidance, or referral criteria relating to the use of injectable pharmacological treatments for overweight and obesity, if held.

**Response:**

1. Hywel Dda University Health Board (UHB) confirms that it is currently providing injectable pharmacological treatments for overweight and obese patients as part of routine services.
  - a. The UHB confirms that the medication Semaglutide (Wegovy) was used as a first-line injectable pharmacological therapy for overweight and obesity until the end of 2025. Pathways for the prescription of Tirzepatide (Mounjaro) are currently in development.

2. The UHB has applied an exemption under Section 21 of the Freedom of Information Act 2000 (FoIA) as the information requested is already in the public domain and is accessible by another means. Information on the UHB's eligibility criteria for patients to access injectable pharmacological treatments for overweight and obesity is available on the UHB's Adult Weight Management Service (WMS) webpage. A link to the webpage has been provided below:

[Adult weight management service - Hywel Dda University Health Board](#)

2. Overweight and obesity treatments are delivered by the UHB's Tier 3 specialist WMS.
2. The UHB confirms it does have an operational pathway and is accepting referrals into the WMS. However, due to the introduction of injectable weight loss medications and the increase in demand for the WMS, the UHB recognises that the current pathway requires updating to meet the needs of patients referred into the WMS.
3. The UHB provides copies of its WMS flow diagram and expedite criteria for the Level 3 Adult WMS, at Attachments 1 and 2.